{
  "files": [
    {
      "assay": "HIC",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophyscial_HICRT.csv",
      "path": "../data/aggregation/jain2017biophyscial_HICRT.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Affinity-Capture",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_ACSINS.csv",
      "path": "../data/aggregation/jain2017biophysical_ACSINS.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "CSI-BLI",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_CSIBLI.csv",
      "path": "../data/aggregation/jain2017biophysical_CSIBLI.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Slope",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_SAS.csv",
      "path": "../data/aggregation/jain2017biophysical_SAS.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "SGAC-SINS",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_SGACSINS.csv",
      "path": "../data/aggregation/jain2017biophysical_SGACSINS.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "AC-SINS",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_ACSINS.csv",
      "path": "../data/aggregation/jain2024assessment_ACSINS.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "CIC",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_CIC.csv",
      "path": "../data/aggregation/jain2024assessment_CIC.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "CS-SINS",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_CSSINS.csv",
      "path": "../data/aggregation/jain2024assessment_CSSINS.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Fab.pI",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_Fab_pI.csv",
      "path": "../data/aggregation/jain2024assessment_Fab_pI.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "HIC",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_HIC.csv",
      "path": "../data/aggregation/jain2024assessment_HIC.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "SEC",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_SEC.csv",
      "path": "../data/aggregation/jain2024assessment_SEC.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "cIEF",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_cIEF.csv",
      "path": "../data/aggregation/jain2024assessment_cIEF.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "HIC",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2018.1475871",
      "key_words": [
        "integrin alpha11",
        "Fv"
      ],
      "name": "jetha2019homology_RT.csv",
      "path": "../data/aggregation/jetha2019homology_RT.csv",
      "study": "Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies",
      "year": 2018,
      "license": "Attribution-NonCommercial-NoDerivatives 4.0 International",
      "size": 97
    },
    {
      "assay": "Heparin",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2019.1683432",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "kraft2019herapin_relrt.csv",
      "path": "../data/aggregation/kraft2019herapin_relrt.csv",
      "study": "Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis",
      "year": 2019,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 128
    },
    {
      "assay": "AC-SINS",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_ACSINS.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_ACSINS.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Red-CGE",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_CGE.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_CGE.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "HIC",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_HICRRT.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_HICRRT.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "NR-CGE",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_NRCGE.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_NRCGE.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "SEC",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_SEC.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_SEC.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Predicted",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-39022-2",
      "key_words": [
        "scFv",
        "SARS-CoV-2 peptide",
        "alphaseq"
      ],
      "name": "li2023machine_scFv-SARS-CoV-2_affinity1.csv.zip",
      "path": "../data/binding/li2023machine_scFv-SARS-CoV-2_affinity1.csv.zip",
      "study": "Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries",
      "year": 2023,
      "license": "Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License",
      "size": 1259701
    },
    {
      "assay": "Predicted",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-39022-2",
      "key_words": [
        "scFv",
        "SARS-CoV-2 peptide",
        "alphaseq"
      ],
      "name": "li2023machine_scFv-SARS-CoV-2_affinity2.csv.zip",
      "path": "../data/binding/li2023machine_scFv-SARS-CoV-2_affinity2.csv.zip",
      "study": "Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries",
      "year": 2023,
      "license": "Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License",
      "size": 1903928
    },
    {
      "assay": "Kd",
      "category": "binding",
      "doi": "https://doi.org/10.48550/arXiv.2506.17857",
      "key_words": [
        "Fv"
      ],
      "name": "AbRank_dataset.csv.zip",
      "path": "../data/binding/AbRank_dataset.csv.zip",
      "study": "AbRank: A Benchmark Dataset and Metric-Learning Framework for Antibody-Antigen Affinity Ranking",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 342357
    },
    {
      "assay": "Kd",
      "category": "binding",
      "doi": "https://doi.org/10.7554/eLife.23156",
      "key_words": [
        "Fv"
      ],
      "name": "adams2017measuring_4420-fluorescein_kd-flow.csv",
      "path": "../data/binding/adams2017measuring_4420-fluorescein_kd-flow.csv",
      "study": "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "year": 2017,
      "license": "Attribution 4.0 International",
      "size": 15
    },
    {
      "assay": "Kd",
      "category": "binding",
      "doi": "https://doi.org/10.7554/eLife.23156",
      "key_words": [
        "scFv",
        "fluorescein",
        "4-4-20"
      ],
      "name": "adams2017measuring_4420-fluorescein_kd-titeseq.csv",
      "path": "../data/binding/adams2017measuring_4420-fluorescein_kd-titeseq.csv",
      "study": "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "year": 2017,
      "license": "Attribution 4.0 International",
      "size": 11052
    },
    {
      "assay": "bind/no",
      "category": "binding",
      "doi": "https://huggingface.co/datasets/COGNANO/AVIDa-hTNFa",
      "key_words": [
        "VHH",
        "human tumor necrosis factor alpha (TNFa)"
      ],
      "name": "cognano_AVIDa-hTNFa.csv",
      "path": "../data/binding/cognano_AVIDa-hTNFa.csv",
      "study": "none",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 5580
    },
    {
      "assay": "Predicted",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41597-022-01779-4",
      "key_words": [
        "scFv",
        "SARS-CoV-2 peptide",
        "alphaseq"
      ],
      "name": "engelhart2022dataset_scFv-SARS-CoV-2_affinity.csv.zip",
      "path": "../data/binding/engelhart2022dataset_scFv-SARS-CoV-2_affinity.csv.zip",
      "study": "A dataset comprised of binding interactions for 104,972 antibodies against a SARS-CoV-2 peptide",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 352140
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "none",
      "key_words": [
        "none"
      ],
      "name": "garbinski2023_kd.csv",
      "path": "../data/binding/garbinski2023_kd.csv",
      "study": "none",
      "year": 2023,
      "license": "none",
      "size": 81
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "C143",
        "SARS-CoV-2-Beta-SP"
      ],
      "name": "hie2023efficient_CoV2Beta_C143_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2Beta_C143_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 17
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "REGN10987",
        "SARS-CoV-Beta-SP"
      ],
      "name": "hie2023efficient_CoV2Beta_REGN10987_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2Beta_REGN10987_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "S309",
        "SARS-CoV-2-WT-S6P"
      ],
      "name": "hie2023efficient_CoV2_S309_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2_S309_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 20
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "REGN10987",
        "SARS-CoV-2-Omicron"
      ],
      "name": "hie2023efficient_CoV2omicron_REGN10987_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2omicron_REGN10987_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 8
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H1-Solomon",
        "MEDI-UCA"
      ],
      "name": "hie2023efficient_MEDIUCA_H1Solomon_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDIUCA_H1Solomon_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 21
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H4-Hubei",
        "MEDI-UCA"
      ],
      "name": "hie2023efficient_MEDIUCA_H4Hubei_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDIUCA_H4Hubei_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 12
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H4-Hubei",
        "MEDI"
      ],
      "name": "hie2023efficient_MEDI_H4Hubei_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDI_H4Hubei_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 16
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H7-HK16",
        "MEDI"
      ],
      "name": "hie2023efficient_MEDI_H7HK16_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDI_H7HK16_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 17
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "Ebola-Virus-GP",
        "mAb114"
      ],
      "name": "hie2023efficient_ebola_mab114_Kd.csv",
      "path": "../data/binding/hie2023efficient_ebola_mab114_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 21
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_multikd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_multikd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 15
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_multikd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_multikd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 15
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_singlekd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_singlekd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_singlekd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_singlekd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top200kd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_top200kd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 50
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top200kd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_top200kd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 182
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top27kd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_top27kd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 28
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top27kd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_top27kd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 27
    },
    {
      "assay": "Octet",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "germline"
      ],
      "name": "jain2024assessment_Hen_Lys_kd.csv",
      "path": "../data/binding/jain2024assessment_Hen_Lys_kd.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 31
    },
    {
      "assay": "Octet",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "Fv",
        "b-Mouse Lysozyme-Fc",
        "germline"
      ],
      "name": "jain2024assessment_mouse_Ly_kd.csv",
      "path": "../data/binding/jain2024assessment_mouse_Ly_kd.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 2
    },
    {
      "assay": "bind/no",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.2412787122",
      "key_words": [
        "Fv",
        "SARS-CoV-2-Wuhan-hu-1",
        "CC12.1",
        "1-20"
      ],
      "name": "kirby2024retrospective_ab-SARSCoV2_binary_kd.csv",
      "path": "../data/binding/kirby2024retrospective_ab-SARSCoV2_binary_kd.csv",
      "study": "Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive",
      "year": 2025,
      "license": "none",
      "size": 1407
    },
    {
      "assay": "Kd",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.2412787122",
      "key_words": [
        "Fv",
        "SARS-CoV-2-Wuhan-hu-1",
        "CC12.1",
        "1-20"
      ],
      "name": "kirby2024retrospective_ab-SARSCoV2_kd.csv",
      "path": "../data/binding/kirby2024retrospective_ab-SARSCoV2_kd.csv",
      "study": "Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive",
      "year": 2025,
      "license": "none",
      "size": 869
    },
    {
      "assay": "-log",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.1613231114",
      "key_words": [
        "Fv",
        "G6.31",
        "VEGF"
      ],
      "name": "koenig2017mutational_kd_g6.csv",
      "path": "../data/binding/koenig2017mutational_kd_g6.csv",
      "study": "Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding",
      "year": 2017,
      "license": "none",
      "size": 4276
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DCC",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DCC_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_DCC_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DCC",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DCC_spr.csv",
      "path": "../data/binding/kothiwal2025htp_DCC_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DKK1",
        "VH1-69",
        "VK3-15",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DKK_1.00_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_DKK_1.00_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 18
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DKK1",
        "VH1-69",
        "VK3-15",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DKK_1.00_spr.csv",
      "path": "../data/binding/kothiwal2025htp_DKK_1.00_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 20
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "IL23R",
        "VH1-69",
        "VK3-15",
        "VK3-20",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_IL23R_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_IL23R_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 56
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "IL23R",
        "VH1-69",
        "VK3-15",
        "VK3-20",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_IL23R_spr.csv",
      "path": "../data/binding/kothiwal2025htp_IL23R_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 70
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "LOX1",
        "VH1-69",
        "VK4-1",
        "VK3-15",
        "VK1-39"
      ],
      "name": "kothiwal2025htp_LOX1_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_LOX1_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 52
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "LOX1",
        "VH1-69",
        "VK4-1",
        "VK3-15",
        "VK1-39"
      ],
      "name": "kothiwal2025htp_LOX1_spr.csv",
      "path": "../data/binding/kothiwal2025htp_LOX1_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 53
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL1",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_PDL1_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_PDL1_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 34
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL1",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_PDL1_spr.csv",
      "path": "../data/binding/kothiwal2025htp_PDL1_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 29
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL2",
        "VH1-69",
        "VK1-39",
        "VK3-15"
      ],
      "name": "kothiwal2025htp_PDL2_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_PDL2_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL2",
        "VH1-69",
        "VK1-39",
        "VK3-15"
      ],
      "name": "kothiwal2025htp_PDL2_spr.csv",
      "path": "../data/binding/kothiwal2025htp_PDL2_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO1",
        "VH1-69",
        "VK4-1",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_ROBO1_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO1_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 45
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO1",
        "VH1-69",
        "VK4-1",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_ROBO1_spr.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO1_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 39
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO2N",
        "VH1-69",
        "VK3-15",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_ROBO2N_hROBO2N_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO2N_hROBO2N_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO2N",
        "VH1-69",
        "VK3-15",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_ROBO2N_hROBO2N_spr.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO2N_hROBO2N_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Syncytin2",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VK3-15",
        "VH1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_Syncytin2_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_Syncytin2_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 48
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Syncytin2",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VK3-15",
        "VH1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_Syncytin2_spr.csv",
      "path": "../data/binding/kothiwal2025htp_Syncytin2_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 51
    },
    {
      "assay": "Cell",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "TIGIT",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_TIGIT_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_TIGIT_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 24
    },
    {
      "assay": "SPR",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "TIGIT",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_TIGIT_spr.csv",
      "path": "../data/binding/kothiwal2025htp_TIGIT_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "ANT",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "ANT",
        "emibetuzumab"
      ],
      "name": "makowksi2022cooptimization_iso_ant.csv",
      "path": "../data/binding/makowksi2022cooptimization_iso_ant.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 126
    },
    {
      "assay": "ANT",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "ANT",
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_igg_ant.csv",
      "path": "../data/binding/makowski2022cooptimization_igg_ant.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 96
    },
    {
      "assay": "OVA",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "OVA",
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_igg_ova.csv",
      "path": "../data/binding/makowski2022cooptimization_igg_ova.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 96
    },
    {
      "assay": "OVA",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "OVA",
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_iso_ova.csv",
      "path": "../data/binding/makowski2022cooptimization_iso_ova.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 126
    },
    {
      "assay": "bind/no",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-024-48072-z",
      "key_words": [
        "Fv",
        "H1HA"
      ],
      "name": "peterson2024integrated_ab_H1HA_binary.csv",
      "path": "../data/binding/peterson2024integrated_ab_H1HA_binary.csv",
      "study": "An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries",
      "year": 2024,
      "license": "Attribution 4.0 International",
      "size": 1071
    },
    {
      "assay": "MAGMA-Seq,",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-024-48072-z",
      "key_words": [
        "Fv",
        "H1HA"
      ],
      "name": "peterson2024integrated_ab_H1HA_kd.csv",
      "path": "../data/binding/peterson2024integrated_ab_H1HA_kd.csv",
      "study": "An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries",
      "year": 2024,
      "license": "Attribution 4.0 International",
      "size": 1040
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr6261",
        "H1"
      ],
      "name": "phillips2021binding_cr6261_h1_kd.csv",
      "path": "../data/binding/phillips2021binding_cr6261_h1_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 953
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr6261",
        "H9"
      ],
      "name": "phillips2021binding_cr6261_h9_kd.csv",
      "path": "../data/binding/phillips2021binding_cr6261_h9_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 921
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr9114",
        "H1"
      ],
      "name": "phillips2021binding_cr9114_h1_kd.csv",
      "path": "../data/binding/phillips2021binding_cr9114_h1_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 32393
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr9114",
        "H3"
      ],
      "name": "phillips2021binding_cr9114_h3_kd.csv",
      "path": "../data/binding/phillips2021binding_cr9114_h3_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 32768
    },
    {
      "assay": "IC50",
      "category": "binding",
      "doi": "https://doi.org/10.1093/bioinformatics/btac439",
      "key_words": [
        "Fv",
        "CoV"
      ],
      "name": "rawat2022abcov_ic50.csv",
      "path": "../data/binding/rawat2022abcov_ic50.csv",
      "study": "Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies",
      "year": 2022,
      "license": "none",
      "size": 427
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1093/bioinformatics/btac439",
      "key_words": [
        "Fv",
        "CoV"
      ],
      "name": "rawat2022abcov_kd.csv",
      "path": "../data/binding/rawat2022abcov_kd.csv",
      "study": "Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies",
      "year": 2022,
      "license": "none",
      "size": 141
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_kd_adalimumab.csv",
      "path": "../data/binding/rosace2023automated_kd_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_kd_golimumab.csv",
      "path": "../data/binding/rosace2023automated_kd_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "ADCC",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_adcc_ec50.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_adcc_ec50.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv",
        "hHER2"
      ],
      "name": "shanehsazzadeh2023unlocking_kd_hher2_fab.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_kd_hher2_fab.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv",
        "hHER2"
      ],
      "name": "shanehsazzadeh2023unlocking_kd_hher2_mab.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_kd_hher2_mab.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_zerokd_trastuzumab.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_zerokd_trastuzumab.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 422
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Afasevikumab",
        "IL17A"
      ],
      "name": "shanehsazzadeh2024igdesign_Afasevikumab-IL17A_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Afasevikumab-IL17A_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 13
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Bimagrumab",
        "ACVR2B"
      ],
      "name": "shanehsazzadeh2024igdesign_Bimagrumab-ACVR2B_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Bimagrumab-ACVR2B_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 24
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Eculizumab",
        "C5"
      ],
      "name": "shanehsazzadeh2024igdesign_Eculizumab-C5_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Eculizumab-C5_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 34
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Osocimab",
        "FXI"
      ],
      "name": "shanehsazzadeh2024igdesign_Osocimab-FXI_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Osocimab-FXI_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 47
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Spesolimab",
        "IL36R"
      ],
      "name": "shanehsazzadeh2024igdesign_Spesolimab-IL36R_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Spesolimab-IL36R_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 40
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Tezepelumab",
        "TSLP"
      ],
      "name": "shanehsazzadeh2024igdesign_Tezepelumab-TSLP_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Tezepelumab-TSLP_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 127
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Utomilumab",
        "TNFRSF9"
      ],
      "name": "shanehsazzadeh2024igdesign_Utomilumab-TNFRSF9_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Utomilumab-TNFRSF9_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 36
    },
    {
      "assay": "Avg",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_Ly1404-BQ.1.1_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_Ly1404-BQ.1.1_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 50
    },
    {
      "assay": "Kd",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_Ly1404-BQ.1.1_Kd.csv",
      "path": "../data/binding/shanker2024unsupervised_Ly1404-BQ.1.1_Kd.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 36
    },
    {
      "assay": "Avg",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "SARS-CoV-2-Wuhan"
      ],
      "name": "shanker2024unsupervised_Ly1404_Wuhan_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_Ly1404_Wuhan_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 33
    },
    {
      "assay": "Avg",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "BA.1"
      ],
      "name": "shanker2024unsupervised_SA58-BA.1_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-BA.1_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 19
    },
    {
      "assay": "Avg",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_SA58-BQ.1.1_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-BQ.1.1_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 49
    },
    {
      "assay": "Kd",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_SA58-BQ.1.1_Kd.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-BQ.1.1_Kd.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 7
    },
    {
      "assay": "Kd",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "XBB.1.5"
      ],
      "name": "shanker2024unsupervised_SA58-XBB.1.5_Kd.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-XBB.1.5_Kd.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 30
    },
    {
      "assay": "bind/no",
      "category": "binding",
      "doi": "https://doi.org/10.48550/arXiv.2306.03329",
      "key_words": [
        "VHH",
        "hIL6"
      ],
      "name": "tsuruta2024avida-hIL6_binary.csv.zip",
      "path": "../data/binding/tsuruta2024avida-hIL6_binary.csv.zip",
      "study": "AVIDa-hIL6: A Large-Scale VHH Dataset Produced from an Immunized Alpaca for Predicting Antigen-Antibody Interactions",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 573892
    },
    {
      "assay": "bind/no",
      "category": "binding",
      "doi": "https://doi.org/10.48550/arXiv.2405.18749",
      "key_words": [
        "VHH",
        "SARS-CoV-2"
      ],
      "name": "tsuruta2024sarscov2_binary.csv.zip",
      "path": "../data/binding/tsuruta2024sarscov2_binary.csv.zip",
      "study": "A SARS-CoV-2 Interaction Dataset and VHH Sequence Corpus for Antibody Language Models",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 77004
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1371/journal.pcbi.1007207",
      "key_words": [
        "d44"
      ],
      "name": "warszawski2019_d44_Kd.csv",
      "path": "../data/binding/warszawski2019_d44_Kd.csv",
      "study": "Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces",
      "year": 2019,
      "license": "Attribution 4.0 International",
      "size": 2049
    },
    {
      "assay": "-log(",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.0603282103",
      "key_words": [
        "4-4-20",
        "fluorescein"
      ],
      "name": "zimmerman2020antibody_4420_kd.csv",
      "path": "../data/binding/zimmerman2020antibody_4420_kd.csv",
      "study": "Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics",
      "year": 2006,
      "license": "none",
      "size": 21
    },
    {
      "assay": "Expression",
      "category": "expression",
      "doi": "https://doi.org/10.7554/eLife.23156",
      "key_words": [
        "4-4-20",
        "fluorescein",
        "Fab"
      ],
      "name": "adams2017measuring_4420-fluorescein_exp_er.csv",
      "path": "../data/expression/adams2017measuring_4420-fluorescein_exp_er.csv",
      "study": "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "year": 2017,
      "license": "Attribution 4.0 International",
      "size": 10970
    },
    {
      "assay": "Expression",
      "category": "expression",
      "doi": "none",
      "key_words": [
        "none"
      ],
      "name": "garbinski2023_exp.csv",
      "path": "../data/expression/garbinski2023_exp.csv",
      "study": "none",
      "year": 2023,
      "license": "none",
      "size": 94
    },
    {
      "assay": "HEK",
      "category": "expression",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_HEK.csv",
      "path": "../data/expression/jain2017biophysical_HEK.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Expression",
      "category": "expression",
      "doi": "https://doi.org/10.1073/pnas.1613231114",
      "key_words": [
        "G6.31",
        "VEGF"
      ],
      "name": "koenig2017mutational_er_g6.csv",
      "path": "../data/expression/koenig2017mutational_er_g6.csv",
      "study": "Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding",
      "year": 2017,
      "license": "none",
      "size": 4276
    },
    {
      "assay": "%ADA",
      "category": "immunogenicity",
      "doi": "https://doi.org/10.1093/bioinformatics/btab434",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "marks2021humanization_immunogenicity.csv",
      "path": "../data/immunogenicity/marks2021humanization_immunogenicity.csv",
      "study": "Humanization of antibodies using a machine learning approach on large-scale repertoire data",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 217
    },
    {
      "assay": "FcRn.Rel.RT.3",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FcRnRelRT3.csv",
      "path": "../data/pharmacokinetics/jain2023identifying_FcRnRelRT3.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 132
    },
    {
      "assay": "Hep.RT.3",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HEPRT3.csv",
      "path": "../data/pharmacokinetics/jain2023identifying_HEPRT3.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 130
    },
    {
      "assay": "FcRn",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2024assessment_FcRn.csv",
      "path": "../data/pharmacokinetics/jain2024assessment_FcRn.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Tg32",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2024assessment_tg32_clearance.csv",
      "path": "../data/pharmacokinetics/jain2024assessment_tg32_clearance.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Tg32",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2024assessment_tg32_halflife.csv",
      "path": "../data/pharmacokinetics/jain2024assessment_tg32_halflife.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "pI",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_pI.csv",
      "path": "../data/pharmacokinetics/makowski2022cooptimization_pI.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 126
    },
    {
      "assay": "FcRn",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_FcRnPeak.csv",
      "path": "../data/pharmacokinetics/shanehsazzadeh2023unlocking_FcRnPeak.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "CLEAR BSD",
      "size": 13
    },
    {
      "assay": "FcRn",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_FcRnRRT.csv",
      "path": "../data/pharmacokinetics/shanehsazzadeh2023unlocking_FcRnRRT.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "FcRn",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_FcRnRT.csv",
      "path": "../data/pharmacokinetics/shanehsazzadeh2023unlocking_FcRnRT.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "BVP",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_BVPELISA.csv",
      "path": "../data/polyreactivity/jain2017biophysical_BVPELISA.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "CIC",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_CICRT.csv",
      "path": "../data/polyreactivity/jain2017biophysical_CICRT.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "ELISA",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_ELISA.csv",
      "path": "../data/polyreactivity/jain2017biophysical_ELISA.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Poly-Specficity",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_PSR.csv",
      "path": "../data/polyreactivity/jain2017biophysical_PSR.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "SMAC",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_SMACRT.csv",
      "path": "../data/polyreactivity/jain2017biophysical_SMACRT.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "DNP",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_DNP.csv",
      "path": "../data/polyreactivity/jain2023identifying_DNP.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 112
    },
    {
      "assay": "FA.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FA2.csv",
      "path": "../data/polyreactivity/jain2023identifying_FA2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Fe.C3.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FVC32.csv",
      "path": "../data/polyreactivity/jain2023identifying_FVC32.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 115
    },
    {
      "assay": "Fe.FVIII.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FvFVIII2.csv",
      "path": "../data/polyreactivity/jain2023identifying_FvFVIII2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 115
    },
    {
      "assay": "Fe.LysM.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FvLysM2.csv",
      "path": "../data/polyreactivity/jain2023identifying_FvLysM2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 115
    },
    {
      "assay": "Heme.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_Heme2.csv",
      "path": "../data/polyreactivity/jain2023identifying_Heme2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Heme.C3.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HemeC32.csv",
      "path": "../data/polyreactivity/jain2023identifying_HemeC32.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Heme.FViii.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HemeFVIII2.csv",
      "path": "../data/polyreactivity/jain2023identifying_HemeFVIII2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Heme.LysM.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HemeLysM2.csv",
      "path": "../data/polyreactivity/jain2023identifying_HemeLysM2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Herapin",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_Herapin_RT.csv",
      "path": "../data/polyreactivity/jain2024assessment_Herapin_RT.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "PSR",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_PSR.csv",
      "path": "../data/polyreactivity/jain2024assessment_PSR.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "CIC",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT1_adalimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT1_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "CIC",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT1_golimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT1_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "CIC",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT2_adalimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT2_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "CIC",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT2_golimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT2_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "cELISA",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_elisa_ec50.csv",
      "path": "../data/polyreactivity/shanehsazzadeh2023unlocking_elisa_ec50.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Polyspecificity",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_polyspecificity.csv",
      "path": "../data/polyreactivity/shanehsazzadeh2023unlocking_polyspecificity.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "APC-MFI",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Elotuzumab",
        "Ixekuzimab",
        "Fv"
      ],
      "name": "shanker2024unsupervised_APC-MFI_Elotuzumab-Ixekuzimab.csv",
      "path": "../data/polyreactivity/shanker2024unsupervised_APC-MFI_Elotuzumab-Ixekuzimab.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 6
    },
    {
      "assay": "APC-MFI",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "Fv"
      ],
      "name": "shanker2024unsupervised_APC-MFI_Ly1404.csv",
      "path": "../data/polyreactivity/shanker2024unsupervised_APC-MFI_Ly1404.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 18
    },
    {
      "assay": "ACP-MFI",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58"
      ],
      "name": "shanker2024unsupervised_APC-MFI_SA58.csv",
      "path": "../data/polyreactivity/shanker2024unsupervised_APC-MFI_SA58.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 15
    },
    {
      "assay": "Tm1",
      "category": "thermostability",
      "doi": "none",
      "key_words": [
        "none"
      ],
      "name": "garbinski2023_tm1.csv",
      "path": "../data/thermostability/garbinski2023_tm1.csv",
      "study": "none",
      "year": 2023,
      "license": "none",
      "size": 86
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "C143"
      ],
      "name": "hie2023efficient_C143_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_C143_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 2
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "MEDIUCA"
      ],
      "name": "hie2023efficient_MEDIUCA_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_MEDIUCA_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 6
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "MEDI"
      ],
      "name": "hie2023efficient_MEDI_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_MEDI_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 2
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "REGN10987"
      ],
      "name": "hie2023efficient_REGN10987_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_REGN10987_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 8
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "S309"
      ],
      "name": "hie2023efficient_S309_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_S309_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 10
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "mAb114UCA"
      ],
      "name": "hie2023efficient_mAb114UCA_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_mAb114UCA_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 2
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "mAb114"
      ],
      "name": "hie2023efficient_mAb114_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_mAb114_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 7
    },
    {
      "assay": "Tm1",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_multitm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_multitm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 15
    },
    {
      "assay": "Tm1",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_singletm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_singletm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "Tm1",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_top200tm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_top200tm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 192
    },
    {
      "assay": "Tm1",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_top27tm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_top27tm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 28
    },
    {
      "assay": "Fab",
      "category": "thermostability",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_Tm.csv",
      "path": "../data/thermostability/jain2017biophysical_Tm.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Fab",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_Tm.csv",
      "path": "../data/thermostability/jain2024assessment_Tm.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_tm1_adalimumab.csv",
      "path": "../data/thermostability/rosace2023automated_tm1_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_tm1_golimumab.csv",
      "path": "../data/thermostability/rosace2023automated_tm1_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "DLS",
      "category": "thermostability",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_DLS.csv",
      "path": "../data/thermostability/shanehsazzadeh2023unlocking_DLS.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "DSF",
      "category": "thermostability",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_DSF1.csv",
      "path": "../data/thermostability/shanehsazzadeh2023unlocking_DSF1.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "DSF",
      "category": "thermostability",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_DSF2.csv",
      "path": "../data/thermostability/shanehsazzadeh2023unlocking_DSF2.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1371/journal.pone.0181490",
      "key_words": [
        "sdAb"
      ],
      "name": "sulea2019assisted_sdAb_tm.csv",
      "path": "../data/thermostability/sulea2019assisted_sdAb_tm.csv",
      "study": "Assisted Design of Antibody and Protein Therapeutics (ADAPT)",
      "year": 2019,
      "license": "Attribution 4.0 International",
      "size": 33
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1093/database/baad021",
      "key_words": [
        "Nanobody"
      ],
      "name": "tresanco2023nbthermo_tm.csv",
      "path": "../data/thermostability/tresanco2023nbthermo_tm.csv",
      "study": "NbThermo: a new thermostability database for nanobodies ",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 673
    }
  ],
  "keys": {
    "assay": [
      "HIC",
      "Affinity-Capture",
      "CSI-BLI",
      "Slope",
      "SGAC-SINS",
      "AC-SINS",
      "CIC",
      "CS-SINS",
      "Fab.pI",
      "SEC",
      "cIEF",
      "Heparin",
      "Red-CGE",
      "NR-CGE",
      "Predicted",
      "Kd",
      "bind/no",
      "-log",
      "Octet",
      "Cell",
      "SPR",
      "ANT",
      "OVA",
      "MAGMA-Seq,",
      "-log(",
      "IC50",
      "ADCC",
      "Avg",
      "Expression",
      "HEK",
      "%ADA",
      "FcRn.Rel.RT.3",
      "Hep.RT.3",
      "FcRn",
      "Tg32",
      "pI",
      "BVP",
      "ELISA",
      "Poly-Specficity",
      "SMAC",
      "DNP",
      "FA.2",
      "Fe.C3.2",
      "Fe.FVIII.2",
      "Fe.LysM.2",
      "Heme.2",
      "Heme.C3.2",
      "Heme.FViii.2",
      "Heme.LysM.2",
      "Herapin",
      "PSR",
      "cELISA",
      "Polyspecificity",
      "APC-MFI",
      "ACP-MFI",
      "Tm1",
      "Tm",
      "Fab",
      "DLS",
      "DSF"
    ],
    "category": [
      "aggregation",
      "binding",
      "expression",
      "immunogenicity",
      "pharmacokinetics",
      "polyreactivity",
      "thermostability"
    ],
    "doi": [
      "https://doi.org/10.1073/pnas.1616408114",
      "https://doi.org/10.1080/19420862.2024.2384104",
      "https://doi.org/10.1080/19420862.2018.1475871",
      "https://doi.org/10.1080/19420862.2019.1683432",
      "https://doi.org/10.1101/2023.01.08.523187",
      "https://doi.org/10.1038/s41467-023-39022-2",
      "https://doi.org/10.48550/arXiv.2506.17857",
      "https://doi.org/10.7554/eLife.23156",
      "https://huggingface.co/datasets/COGNANO/AVIDa-hTNFa",
      "https://doi.org/10.1038/s41597-022-01779-4",
      "none",
      "https://doi.org/10.1038/s41587-023-01763-2",
      "https://doi.org/10.1080/19420862.2024.2362775",
      "https://doi.org/10.1073/pnas.2412787122",
      "https://doi.org/10.1073/pnas.1613231114",
      "https://doi.org/10.1101/2025.05.15.650607",
      "https://doi.org/10.1038/s41467-022-31457-3",
      "https://doi.org/10.1038/s41467-024-48072-z",
      "https://doi.org/10.7554/elife.71393",
      "https://doi.org/10.1093/bioinformatics/btac439",
      "https://doi.org/10.1038/s41467-023-37668-6",
      "https://doi.org/10.1101/2023.12.08.570889",
      "https://doi.org/10.1126/science.adk8946",
      "https://doi.org/10.48550/arXiv.2306.03329",
      "https://doi.org/10.48550/arXiv.2405.18749",
      "https://doi.org/10.1371/journal.pcbi.1007207",
      "https://doi.org/10.1073/pnas.0603282103",
      "https://doi.org/10.1093/bioinformatics/btab434",
      "https://doi.org/10.1080/19420862.2023.2200540",
      "https://doi.org/10.1371/journal.pone.0181490",
      "https://doi.org/10.1093/database/baad021"
    ],
    "key_words": [
      "",
      "XBB.1.5",
      "Nanobody",
      "Spesolimab",
      "hHER2",
      "ANT",
      "Osocimab",
      "VH1-39",
      "CC12.1",
      "scFv",
      "H1-Solomon",
      "germline",
      "TNFRSF9",
      "REGN10987",
      "PDL2",
      "Ebola-Virus-GP",
      "H9",
      "emibetuzumab",
      "MEDIUCA",
      "G6.31",
      "SARS-CoV-2",
      "ROBO1",
      "DKK1",
      "H4-Hubei",
      "Fv",
      "Fab",
      "MEDI",
      "cr6261",
      "LOX1",
      "d44",
      "VK1-39",
      "Eculizumab",
      "Afasevikumab",
      "CoV",
      "Elotuzumab",
      "S309",
      "hIL6",
      "Ixekuzimab",
      "H3",
      "VEGF",
      "VK3-20",
      "alphaseq",
      "NIP228",
      "ROBO2N",
      "SARS-CoV-2-Beta-SP",
      "integrin alpha11",
      "H1HA",
      "VHH",
      "BQ.1.1",
      "Tezepelumab",
      "SARS-CoV-2-Omicron",
      "b-Mouse Lysozyme-Fc",
      "FXI",
      "TSLP",
      "1-20",
      "Syncytin2",
      "IL36R",
      "H7-HK16",
      "SARS-CoV-2-WT-S6P",
      "mAb114",
      "C5",
      "H1",
      "cr9114",
      "SARS-CoV-2 peptide",
      "Bimagrumab",
      "MEDI-UCA",
      "SARS-CoV-Beta-SP",
      "clinical stage therapeutic",
      "IL17A",
      "trastuzumab",
      "TIGIT",
      "BA.1",
      "Trastuzumab",
      "SARS-CoV-2-Wuhan",
      "none",
      "VK3-15",
      "mAb114UCA",
      "IL23R",
      "DCC",
      "4-4-20",
      "ACVR2B",
      "OVA",
      "Adalimumab",
      "sdAb",
      "fluorescein",
      "Utomilumab",
      "Ly1404",
      "SA58",
      "PDL1",
      "hen egg lysozyme (HEL)",
      "VK4-1",
      "human tumor necrosis factor alpha (TNFa)",
      "SARS-CoV-2-Wuhan-hu-1",
      "C143",
      "VH1-69",
      "Golimumab"
    ],
    "study": [
      "Biophysical properties of the clinical-stage antibody landscape",
      "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies",
      "Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis",
      "Unlocking de novo antibody design with generative artificial intelligence",
      "Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries",
      "AbRank: A Benchmark Dataset and Metric-Learning Framework for Antibody-Antigen Affinity Ranking",
      "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "none",
      "A dataset comprised of binding interactions for 104,972 antibodies against a SARS-CoV-2 peptide",
      "Efficient evolution of human antibodies from general protein language models",
      "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive",
      "Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding",
      "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries",
      "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies",
      "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "AVIDa-hIL6: A Large-Scale VHH Dataset Produced from an Immunized Alpaca for Predicting Antigen-Antibody Interactions",
      "A SARS-CoV-2 Interaction Dataset and VHH Sequence Corpus for Antibody Language Models",
      "Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces",
      "Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics",
      "Humanization of antibodies using a machine learning approach on large-scale repertoire data",
      "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "Assisted Design of Antibody and Protein Therapeutics (ADAPT)",
      "NbThermo: a new thermostability database for nanobodies "
    ],
    "year": [
      2006,
      2017,
      2018,
      2019,
      2021,
      2022,
      2023,
      2024,
      2025
    ],
    "license": [
      "none",
      "Attribution-NonCommercial 4.0 International",
      "Attribution-NonCommercial-NoDerivatives 4.0 International",
      "Clear BSD",
      "Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License",
      "Attribution 4.0 International",
      "MIT License",
      "CLEAR BSD"
    ],
    "size": [
      137,
      43,
      97,
      128,
      13,
      1259701,
      1903928,
      342357,
      15,
      11052,
      5580,
      352140,
      81,
      17,
      14,
      20,
      8,
      21,
      12,
      16,
      22,
      23,
      50,
      182,
      28,
      27,
      31,
      2,
      1407,
      869,
      4276,
      18,
      56,
      70,
      52,
      53,
      34,
      29,
      45,
      39,
      48,
      51,
      24,
      126,
      96,
      1071,
      1040,
      953,
      921,
      32393,
      32768,
      427,
      141,
      5,
      422,
      47,
      40,
      127,
      36,
      33,
      19,
      49,
      7,
      30,
      573892,
      77004,
      2049,
      10970,
      94,
      217,
      132,
      130,
      112,
      113,
      115,
      6,
      86,
      10,
      192,
      673
    ]
  }
}